Background Malignant pleural mesothelioma (MPM) remains a challenging disease to
manage. In the past few decades, extrapleural pneumonectomy (EPP), pemetrexed-based …

Aims Malignant pleural mesothelioma (MPM) is an aggressive malignancy with poor
prognosis and limited treatment options. Cisplatin plus pemetrexed is the only approved first …

7500 Background: MPM median overall survival (OS) did not exceed 13 months with
pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular …

Background: The programmed death receptor 1 (PD-1) pathway is implicated in evasion of
the antitumor immune response. Pembrolizumab is a potent, highly selective humanized …

Objectives Currently there are many uncertainties in the optimal treatment of malignant
pleural mesothelioma (MPM), this is reflected in discrepancies between current guidelines …

Aim: To assess real-world treatment patterns and outcomes among patients with advanced
malignant pleural mesothelioma. Patients & methods: Retrospective database analysis …

Background Overall survival (OS) for malignant pleural mesothelioma (MPM) in vulnerable
subgroups remains poorly understood with scarce data available to guide treatment …

Chinese Medical Journal¦ January 5, 2017¦ Volume 130¦ Issue 1 2 was increased in the
bevacizumab plus chemotherapy when compared with chemotherapy alone. The NCCN …

Introduction Unresectable pleural mesothelioma is a poor prognosis disease. Improvement
in overall survival (OS) has been shown with PEMETREXED combined with CISPLATIN …

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for
Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic …